On Friday, CEL-SCI Corporation (NYSEMKT:CVM)’s shares declined -5.17% to $0.750.
CEL-SCI Corporation (CVM) declared that it has priced a best efforts offering of common stock and warrants at a combined price of $0.79 per unit of securities for aggregate gross proceeds of up to $16 million, preceding to deducting placement agent commissions and offering expenses. Each unit comprises of one share of common stock and one warrant to purchase one share of common stock. The common stock and warrants will separate right away. The warrants are right away exercisable, expire in five-years and have an exercise price of $0.79 per share. This offering is predictable to close on or about May 28, 2015, subject to the satisfaction of customary closing conditions.
CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, an ongoing Phase I study in HIV/HPV co-infected patients other research and development, repayment of a $1.1 million note, held in a trust of which the Company’s chief executive officer is the trustee and a beneficiary, due in July 2015 and general and administrative expenses.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s shares dropped -4.59% to $8.10.
Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), and BioDelivery Sciences International, Inc. (BDSI) presented pivotal data from two Phase 3 studies for investigational study drug buprenorphine HCL buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA®) drug delivery technology. The findings, presented at the American Pain Society’s 34th Annual Scientific Meeting in Palm Springs, CA , showed BEMA® buprenorphine compriseently reduced pain scores contrast to placebo. The drug is presently under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date in October 2015 , for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The Phase 3 studies were both double-blind, randomized, placebo-controlled, enriched-enrollment studies in patients with chronic lower back pain. A total of 971 randomized patients accomplished both trials, counting pain sufferers who either had received opioid therapy (study EN3409-307; abstract 437) or were opioid-naive at the start of the study (study EN3409-308; abstract 439). The studies comprised of an open-label period in which patients were titrated to a tolerated, effective dose of BEMA® buprenorphine then randomized to either continue on BEMA® buprenorphine or receive a placebo buccal film. The primary endpoint of both studies was change in the average daily pain score from baseline to week 12 of double-blind treatment following the open-label titration period. BEMA® buprenorphine is delivered using BDSI’s patented BEMA® drug delivery technology, which efficiently and conveniently delivers buprenorphine across the buccal mucosa (inside lining of the cheek).
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction.
At the end of Friday’s trade, InterCloud Systems Inc (NASDAQ:ICLD)‘s shares dipped -4.46% to $3.21.
InterCloud Systems Inc (ICLD) stated financial results for the first quarter of 2015.
1st Quarter Financial Highlights:
- Revenue raised 49% year-over-year to $21.0 million
- Gross Profit raised 87% year-over-year to $7.4 million
- Gross Profit Margin raised year over year from 28% to 35%
- Adjusted EBITDA of $598,000 contrast to $(1.5) million in the first quarter of 2014
InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally.
Ross Stores, Inc. (NASDAQ:ROST), ended its Friday’s trading session with -4.45% loss, and closed at $97.03.
Ross Stores, Inc. (ROST) declared that the Company’s Board of Directors declared a regular quarterly cash dividend of $.235 per common share, payable on June 30, 2015 to stockholders of record as of June 9, 2015. Adjusting for the formerly declared two-for-one stock split effective on June 11, 2015, the quarterly cash dividend will be $.1175 per share post-split.
Ross Stores, Inc. is an S&P 500, Fortune 500 and Nasdaq 100 (ROST) company headquartered in Dublin, California, with fiscal 2014 revenues of $11.0 billion. The Company operates Ross Dress for Less® (“Ross”), the largest off-price apparel and home fashion chain in the United States with 1,242 locations in 33 states, the District of Columbia and Guam as of May 2, 2015. Ross offers first-quality, in-season, name brand and designer apparel, accessories, footwear and home fashions for the entire family at everyday savings of 20% to 60% off department and specialty store regular prices.
Ross Stores, Inc., together with its auxiliaries, operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dds DISCOUNTS brand names in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
